No Detail Found!

Efficacy of octreotide in cases of inoperablehepatocellular carcinoma: a clinical trial

Author(s)
Javed Iqbal Farooqai Rahim MedicalCentreG,.T. Road, PeshawarCity,Pakistan
Rukhsana Javed Farooqi Rahim Medical Centre, G.T. Road, Peshawar City, Pakistan
Abstract
A study was conducted to assess the clinical efficacy of high-dose octreotide in the treatment of hepatocellular carcinoma. Thirteen patients with advanced hepatocellular carcinoma were randomised to receive either 250pg subcutaneous octreotide twice daily (6 patients) or no treatment (7 patients). Both groups were comparable with respect to baseline characteristics. The study showed significant improvement in the quality of life amongst the treatment group as compared to the control group (P< 0.05). The liver enzymes and serum a -feto proteins (AFP) concentrations were improved significantly in the treatment group as compared to the control group. No serious side effects were found in the treatment group. We conclude that high-dose octreotide significantly improves quality of life that may improve survival; and is a valuable alternative in the treatment of inoperable hepatocellular carcinoma.
Publication Details
Page(s) 258-260
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 10, Issue: 7, Year: 2000

Request the full text from PASTIC

Keywords
Hepatocellular carcinoma Octreotide
References
Ragaz J .1988 .Hepatocellular carcinoma: a comparison of oriental and Caucasianpatients. AmJSurg, 155 : 659-62.
Wong F,Choi TK .1988 .Surgery of liver and Biliary tract. LondonC:hurchillLivingstone, : 1135-51.
Ahmed M,Qureshi MS,ZuberiSJ MS .1979 .; role in the epidemiology of liver diseases. JPMA, 29 : 23-7.
Chao Y,Chan WK,Huang YS,Teng HC,Wang SS,Lui WY .1996 .eta! Phase II of flutamide in the treatment of hepatocellularcarcinoma. Cancel, 77 : 635-9.
Ram AM,Novell JR,Suppl I) . .Intraarterial radiotherapy with 131 iodine-lipiodol for irresectable hepatocellular carcinoma. , : A17.
Madden MV,Krige E.,Baily S,Beningfield ST .1993 .Randomised trial of targeted chemotherapy with lipiodol and 5 epidoxorubicin compared with symptomatic treatment for hepatoma. Gut, 34 : 1598-600.
Rossi P,Rossi M,Clementi M,Pizzamigho M.Bezzi M . .SalvatorFiM. Proc Euro SemDiaginternRadio! Herakhon1, 994 : 315-20.
Novell JR,Dick R,Hobbs KE .1995 .Epirubicin-lipiodal chemotherapy versus 131 iodine - lipioidol radiotherapyin the treatment of unresectable hepatocellular carcinoma. Cancer, 76 : 2202-10.
de HerderWW .1996 .. Hofland IJ. Octreotide. NEngJMed, 334 : 246-54.
Reubi JC,Kvols L . .Distribution of somatostain receptors in normal and tumor tissue. Metabolism, 39(Suppl 2) : 78-81.
Reubi JC .1991 .The role of somatostotin and its analogues, in the diagnosis and treatment of tumors. EndocRev, 12 : 450-82.
Thermos K,Vasilaki A .1998 .Treatment of hepatocellular carcinoma with octretide; a randomised controlled study. Gut, 42 : 442-7.
.1994 .Subtype selectivity of peptide analogues for all five cloned human somatostain receptors (hsstr 1-5. Endocrinology, 125 : 2814-7.
Yamada Y,Shimatsu A .1994 .-995 in treatment of human endocrine tumors. JCiin invest, 93 : 1321-5.
.1994 .All five cloned human somatostatinreceptors (hsstr 1-5) are functionally coupled to adenyl cyclase. Biochem Biophys Res Common, 198 : 605-12.
Reily C .1989 .Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc NatAcadSci USA, 86 : 2003-7.
Scholly AV,Reeding TW .1987 .Somatostain analogue as adjuncts to agonists of lutenizing hormone releasing hormone in the treatment of experimental prostate cancer. Proc NatAcadSciUSA, 72 : 75-9.
Caplin ME .1996 .The CCK-K gastrin receptor. hepatocellulor carcinomaGut, (Suppl 1) : A16.
Piva A,Miguet P Dhumeaux D . .Treatment of hepatoceller carcinoma. in hepatology 93: ParisohnLibbey Eurptext1, 993 : 18-22.
0

Citations

0

Downloads

88

Views